The EPS beat is modest and the wider loss is expected for a clinical-stage biotech. The real catalysts are the OPERA-01 top-line data (fall 2026) and OP-3136 ASCO data (late May/June). Monitor these events for binary outcomes that could move the stock 30-50%.
Price Chart
Executive Summary
Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $30.4M a year ago due to increased R&D spending on late-stage trials. The stock is driven by upcoming catalysts: top-line Phase 3 OPERA-01 data expected fall 2026 and initial Phase 1 OP-3136 data at ASCO this month.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.52 vs consensus -$0.54 (7.2% beat)
- Net loss $53.1M vs $30.4M YoY, driven by higher R&D spend
- Cash position $505.3M as of March 31, 2026
- Top-line Phase 3 OPERA-01 data expected fall 2026
- Initial Phase 1 OP-3136 data to be presented at ASCO May/June 2026
- Phase 3 OPERA-02 enrollment continuing
Financial Impact
Net loss increased 75% YoY to $53.1M; cash burn rate ~$53M/quarter
Risk Factors
- Phase 3 OPERA-01 failure would be a severe negative catalyst
- Cash burn rate implies ~2.5 years of runway; potential dilution risk
- OP-3136 Phase 1 safety/efficacy data could disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292656 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 10, 2026 7w ago | Press Release | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 9, 2026 7w ago | Institutional Cluster | $11.94 $10.99 | ▲ +8.00% | ▲ +7.08% | $8.23 (+31.11%) |
May 26, 2026 18w ago | 8-K | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 26, 2026 18w ago | Press Release | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 21, 2026 19w ago | 8-K | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 21, 2026 19w ago | Press Release | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 12, 2026 20w ago | 8-K | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
May 12, 2026 20w ago | Press Release | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
Apr 29, 2026 22w ago | DEFA14A | $14.41 $13.19 | ▼ −8.47% | ▼ −13.69% | $8.23 (−42.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access